Breakout Setups
TYRA appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
TYRA BIOSCIENCES INC (TYRA) Stock Price & Overview
NASDAQ:TYRA • US90240B1061
Current stock price
36.69 USD
+2.32 (+6.75%)
At close:
36.68 USD
-0.01 (-0.03%)
After Hours:
The current stock price of TYRA is 36.69 USD. Today TYRA is up by 6.75%. In the past month the price increased by 0.47%. In the past year, price increased by 265.44%.
TYRA Key Statistics
52-Week Range8.75 - 40.65
Current TYRA stock price positioned within its 52-week range.
1-Month Range33.61 - 40.65
Current TYRA stock price positioned within its 1-month range.
- Market Cap
- 1.976B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.01
- Dividend Yield
- N/A
TYRA Stock Performance
Today
+6.75%
1 Week
+4.03%
1 Month
+0.47%
3 Months
+20.81%
Longer-term
6 Months +157.84%
1 Year +265.44%
2 Years +114.56%
3 Years +158.93%
5 Years N/A
10 Years N/A
TYRA Stock Chart
TYRA Stock Screens
TYRA currently appears in the following ChartMill screener lists.
TYRA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TYRA. When comparing the yearly performance of all stocks, TYRA is one of the better performing stocks in the market, outperforming 97.68% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TYRA. While TYRA has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TYRA Earnings
Next Earnings DateApr 30, 2026
Last Earnings DateMar 2, 2026
PeriodQ4 / 2025
EPS Reported-$0.57
Revenue Reported
EPS Surprise -5.80%
Revenue Surprise %
TYRA Forecast & Estimates
18 analysts have analysed TYRA and the average price target is 51 USD. This implies a price increase of 39% is expected in the next year compared to the current price of 36.69.
Analysts
Analysts87.78
Price Target51 (39%)
EPS Next Y-22.8%
Revenue Next YearN/A
TYRA Groups
Sector & Classification
TYRA Financial Highlights
Over the last trailing twelve months TYRA reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -33.11% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-119.95M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.44% | ||
| ROE | -46.28% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-32.56%
Sales Q2Q%N/A
EPS 1Y (TTM)-33.11%
Revenue 1Y (TTM)N/A
TYRA Ownership
Ownership
Inst Owners108.15%
Shares53.87M
Float52.24M
Ins Owners2.93%
Short Float %15.82%
Short Ratio7.72
TYRA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TYRA
Company Profile
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 87 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Company Info
IPO: 2021-09-15
TYRA BIOSCIENCES INC
2656 State Street
Carlsbad CALIFORNIA US
CEO: Todd Harris
Employees: 87
Phone: 16197284760
TYRA BIOSCIENCES INC / TYRA FAQ
What does TYRA do?
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 87 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Can you provide the latest stock price for TYRA BIOSCIENCES INC?
The current stock price of TYRA is 36.69 USD. The price increased by 6.75% in the last trading session.
What is the dividend status of TYRA BIOSCIENCES INC?
TYRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TYRA stock?
TYRA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of TYRA stock?
TYRA BIOSCIENCES INC (TYRA) operates in the Health Care sector and the Biotechnology industry.
Who owns TYRA BIOSCIENCES INC?
You can find the ownership structure of TYRA BIOSCIENCES INC (TYRA) on the Ownership tab.